Cubist Pharmaceutical (CBST) Stock Declines Today Following Patent Rejection

NEW YORK (TheStreet) -- Cubist Pharmaceuticals (CBST) shares are down 4.3% to $96.27 in trading on Tuesday, a day after the biopharmaceutical company agreed to be purchased by Merck (MRK) for $8.4 billion. Just hours after the announcement of the deal, Cubist had four of the patents for its top selling drug revoked by a U.S. court.

Cubist shares spiked more than 30% yesterday following Merck's acquisition announcement, however the profitability of the company was called into question after a court rejected all but one of the patents covering Cubicin, the company's bacterial skin infection treatment that generated $700 million in sales during the first nine months of 2014.

The ruling allows for competitors to begin production of generic versions of the drug by 2016.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Merck released a statement saying that it still expects the company to generate at least $1 billion in revenue next year and sees growth potential in the company going forward regardless of yesterday's decision.

TheStreet's Jim Cramer has further coverage of the deal here.

TheStreet Ratings team rates CUBIST PHARMACEUTICALS INC as a Buy with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:

"We rate CUBIST PHARMACEUTICALS INC (CBST) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, robust revenue growth, good cash flow from operations, increase in stock price during the past year and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

CBST Chart CBST data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists